Kalorama Information expects the market for plasma collection to grow, and to outpace overall blood collection through 2018. The primary market driver will be plasma-derived immunoglobulins used to produce intravenous immunoglobulin therapies.åÊThe growth of mature markets associated with the collection, processing and therapeutic use of whole blood and derived products are by and large endangered without the robustness of the global plasma market. This is the finding of Kalorama Information's recent Report, "Blood:åÊThe Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products."
Source plasma ÛÒ collected with machines that separate and transfuse red blood cells back into the donor (apheresis) ÛÒ rose by 11% on average each year over the same period. Kalorama Information expects the plasma Ig market to grow by over 6% annually through 2018.
"Lower transfusion rates have been the result of reformed hospital practices; medical advances that mitigate the need for transfusion; and autologous blood salvaging," said Bruce Carlson, Publisher of Kalorama Information.åÊ"In turn, insurance companies have reduced rates for transfusion procedures and hospitals now seek out lower blood unit prices."
Kalorama Information's market research report says over 10 times as much plasma is collected in the United States as in Europe ÛÒ in 2013, 29.4 million liters to 2.3 million liters. The vast majority of source plasma is collected by private (for-profit) industry. National governments once active in plasma markets through blood fractionation activities have since ceded collection to plasma specialists in the pharmaceutical industry and not-for-profit blood collection organizations.
The production of not-for-profit participants has become increasingly insufficient toward meeting regional plasma demand. Plasma collection from the fractionation of whole blood has remained largely flat in volume for over the past decade, with source plasma responsible for supplying rising demand. While national self-sufficiency in plasma collection is not necessary across the board, better distribution globally of large-scale plasma facilities ÛÒ outside of hubs in the United States, some EU countries and Australia ÛÒ could stimulate higher demand from neglected markets. The majority of countries in the world consume plasma-derived products at rates well below their potential usage as suggested by disease prevalence.
Kalorama says the sustained success of the plasma market, even through the downturn of the whole blood market ensures growth in many blood-related markets. Strong growth in infectious disease screening for blood banks and plasma collection facilities is predicated on the equally valid demand for screening after plasmapheresis. Blood typing and blood collection equipment will see relatively lower growth rates attributable to plasma collection as consolidation is also a key characteristic of the modern plasma industry.
According to AudienceSCAN data, 1.8% of U.S. adults plan to sell blood and/or blood plasma in the next 12 months. A surprising 52% are women. 38% of sellers are between the ages of 18 and 24, and are 175% more likely than the average American to sell their blood.
Chances are, these donors are divorced and single: 60%. 38% bring home less than $25,000 annually. Another 38% live in the suburbs, but a close 37% live in urban settings. This audience could be saving up to take mom out ÛÒ 40% celebrated Mother's Day at a restaurant.
40% of blood sellers responded to an ad on a social network in the past 30 days. And 37% took action from a mobile smartphone app or text message ad. Just what are they spending that hard-earned blood money on? 51% will take a trip to an amusement park this year. Another 37% are 161% more likely than the average consumer to buy a video game system.
AudienceSCAN data is available as part of a subscription to AdMall for Agencies. Media companies can access AudienceSCAN data through the Audience Intelligence Reports inåÊAdMall.